Frank Watanabe, Arcutis Biotherapeutics CEO

Ar­cutis tacks on atopic der­mati­tis ap­proval for Zo­ryve cream

The FDA ap­proved Ar­cutis Bio­ther­a­peu­tics’ skin treat­ment Zo­ryve to treat mild to mod­er­ate atopic der­mati­tis in adults and some chil­dren, the

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.